Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Long-Term Debt of $0.00 for fiscal year 2023.
Corbus Pharmaceuticals Holdings, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $0.00 | -100.0% |
| 2022 | $15.98M | +2.2% |
| 2021 | $15.64M | -13.3% |
| 2020 | $18.03M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $11.32M | -2.5% | -19.0% |
| March 31, 2023 | $13.97M | +1.8% | -12.6% |
| December 31, 2022 | $15.98M | +2.2% | +70.3% |
| September 30, 2022 | $9.39M | -49.4% | -19.2% |
| June 30, 2022 | $11.61M | -36.8% | -15.4% |
| March 31, 2022 | $13.73M | -24.6% | -12.2% |
| December 31, 2021 | $15.64M | -13.3% | -15.7% |
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2023 period, Corbus Pharmaceuticals Holdings, Inc.’s long-term debt has declined by 100.0% (from $18.03 million to $0.00).
- The most recent figure is from Corbus Pharmaceuticals Holdings, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 12, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: